Abstract
Oral cancer is aggressive and invasive. The 5-year survival rate is around 50% and has not improved in over 50 years. One-third of oral cancer patients develop local and/or regional tumor recurrence following treatment. We continue to use our multicellular spheroid (MCS) model to better understand how the extracellular matrix contributes to epithelial to mesenchymal transition and how hypoxia contributes to the progression of oral squamous cell carcinoma (SCC).
Oral cancer is the sixth most common type of cancer in the world. In the United States, 37,000 new cases are diagnosed annually and each year 8,000 individuals die from this disease (1). Squamous cell carcinoma (SCC) makes up 96% of all oral cancers (2). Despite advances in treatment, the prognosis for oral SCC has not improved in over 50 years. The 5-year survival rate for oral SCC is approximately 50% (3). The poor prognosis of SCC is due to invasion and local recurrence. Interactions between primary SCC cells and the surrounding extracellular matrix (ECM) facilitate invasion. As a tumor grows its available resources, including oxygen availability, become extremely limited which may affect tumor cell behavior. In this study, we aimed to determine the effect of hypoxia on EMT in OSCC spheroids.
SCC cells undergo a transformative process known as epithelial-mesenchymal transition (EMT). EMT is a process by which epithelial cells lose their cell polarity, decrease cell-cell adhesion, and gain migratory and invasive properties. EMT involves changes in expression, distribution, and function of a number of proteins for cells to transition between the epithelial and mesenchymal phenotype. During EMT, E-cadherin expression is lost; thereby disrupting desmosomes, promoting invasion and de-differentiation (4). N-cadherin acquisition also promotes invasive SCC behavior (4, 5).
Previous studies show that the αvβ6 integrin, an epithelial specific integrin, is instrumental to EMT in colorectal and oral cancer (6, 7). The αvβ6 integrin is an epithelial-specific adhesion receptor normally not expressed in oral keratinocytes. However, upon wounding or neoplastic transformation, αvβ6 is highly expressed by the same keratinocytes. The αvβ6 integrin is an adhesion receptor for fibronectin (FN) and tenascin-C, and also activates TGFβ1 (8, 9). Binding of αvβ6 integrin to FN results in the activation of FYN kinase in oral SCC. The activation of FYN kinase promotes activation of RAF/MAPK which induces EMT (10). Our laboratory demonstrated that expression of the full-length β6 subunit is required for maintenance of the mesenchymal phenotype thus promoting EMT (7).
Keratins are the major structural components of the epithelial cell cytoskeleton and play a strategic role in their architectural integrity (11). It has been shown that gene mutations in keratin are responsible for a large number of inherited skin disorders thus, reinforcing their role in structural integrity of the epithelium (11). In addition to cytoskeletal changes, it is a common process for the ECM to undergo a variety of changes during tumor progression. For example, as breast tissue undergoes dysplastic changes there is a shift in the deposition of FN, which induces EMT (12).
Tumor hypoxia is strongly associated with tumor growth and malignant progression. Hypoxia is a non-physiological level of oxygen tension, a common phenomenon in a majority of malignant tumors (13). Tumor-hypoxia can alter vascularization and help the acquisition of epithelial-to-mesenchymal transition phenotype, which can result in enhanced cell mobility and metastasis (15). Hypoxia in the tumor microenvironment may also play a role in conferring resistance to therapy and it is currently a focus of cancer treatment since many solid tumors display an additional growth advantage through their ability to survive in a hypoxic environment (14). HIF1α is up-regulated by oxygen deprivation and is associated with increased patient mortality in several cancer types (15). As a tumor grows its available resources, including oxygen availability, become extremely limited which may affect tumor cell behavior. In this study, we aimed to determine the effect of hypoxia on EMT in OSCC spheroids.
Materials and Methods
Cell lines. The SCC9 cell line was derived from a base of tongue cancer and was a generous gift from Dr. James Reinwald (Brigham and Woman's Hospital, Harvard School of Medicine). The SCC9β6 cell line was established by stable transfection of SCC9 cells with full length β6 cDNA (17). SCC9β6 cells were transduced with the kinase-dead (KD) Fyn cDNA in order to establish the SCC9β6KDFyn cell line using the Retro-X system (Clontech, Mountain View, CA, USA) (16,17). The SCC9 cells were transduced with constitutively active (CA) Fyn cDNA to establish the SCC9CAFyn cells using the Retro-X system (Clontech, Mountain View, CA, USA) (10). The KDFyn cDNA was a generous gift from Dr H. Kawakatsu (University of California, San Francisco). The cDNA for the full-length β6 was a generous gift from Dr. Dean Sheppard (University of California, San Francisco).
Generation of Multicellular Spheroids. Tissue culture plates (Santa Cruz Biotechnology, Dallas, TX, USA) were treated with a 0.6% agarose solution and air-dried overnight at room temperature. Cells were harvested from monolayer cultures with 0.25% trypsin-EDTA and rinsed twice to remove serum. The cells were then placed on agarose-coated plates and allowed to form multicellular spheroids for 48 h at 37°C in 5% CO2 in serum free media.
Antibodies. Rabbit monoclonal antibodies to vimentin (clone R28) (CST#3932) (1:1000 dilution), HIF1α (CST #3716) (1:1,000 dilution), and β-actin (clone 13E5) (CST#4970) (1:1,000 dilution) were purchased from Cell Signaling Technology Inc.(Danvers, MA, USA). Mouse monoclonal antibody to pan-keratin (clone C11) (CST #4545) (1:1,000 dilution) was purchased from Cell Signaling Technology Inc., (Danvers, MA, USA). Mouse monoclonal antibody to fibronectin (clone FN-15) (1:800 dilution) was purchased from Sigma Aldrich (St. Louis, MO, USA). Horseradish peroxidase (HRP)-conjugated anti-rabbit antibodies (CST#7074) (1:2,000 dilution) and HRP-conjugated anti-mouse antibodies (CST #7076) (1:2,000 dilution) were purchased from Cell Signaling Technology Inc. Cobalt (II) chloride hexahydrate (C8661) (100 μM) was purchased from Sigma Aldrich (St. Louis, MO, USA).
Western blot. Cells were grown as a monolayer or as a multicellular spheroid (MCS) in serum-free media for 48 h prior to lysing. Cells were rinsed with ice-cold 1X PBS and lysed. Total protein was extracted from cells with RIPA lysis buffer (50 mM Tris pH 8, 150 mM NaCl, 0.2% SDS, 1% deoxycholic acid, 1% Triton X-100, and complete protease inhibitor tablet). Lysate was generated by suspending MCS in RIPA lysis buffer, vortexing, and then forcing MCS suspension through a 30-gauge needle. Monolayer lysate was generated by pipetting RIPA lysis buffer over the culture and scraped with a cell scraper. Twenty μg of protein per cell line was resolved by SDS-PAGE and transferred to a PVDF membrane using a semi-dry apparatus (Bio-Rad, Hercules, CA, USA). Membranes were incubated with monoclonal antibodies overnight at 4°C. After washing, the blots were incubated with HRP-conjugated anti-rabbit antibodies for 40 minutes. The blots were then treated with ECL substrate (Thermo Scientific Pierce; Rockford, IL, USA) and exposed to x-ray film (Santa Cruz Biotechnology). Western Blot images were quantified using NIH Image J (Image J reference) (18). β-actin or tubulin were used as control bands to quantify the image. The images were digitally captured and assigned relative value units based on the intensity of the signal. To establish relative value units, the ImageJ was used toolbar to draw a rectangle around the control lane (tubulin or actin). This is repeated for each peak. Each peak with its size, is expressed as a percentage of the total size of all of the highlighted peaks. Each subsequent percentage is then divided by the percentage of the assigned control.
Results
Expression of keratin is differentially expressed by cells lines and multicellular spheroids. To evaluate keratin expression, the oral SCC cell lines were grown serum-free, either as a monolayer or MCS for 48 h. The cells were lysed, normalized, and evaluated for expression of keratin by western blot analysis. The blots were scanned, digitized and assigned a relative value unit (rvu).
When grown as a monolayer and processed for western blot analysis, SCC9 cells were assigned an rvu of 1.0 (Figure 1). This was in contrast to the SCC9β6 and the SCC9CAFyn cell lines, which were assigned relative value units of 2.0 (Figure 1). Keratin was undetectable in the SCC9β6KDFyn cell line. However, when cells were grown as multicellular spheroids, keratin expression was up-regulated by all cell lines compared to their corresponding monolayers. SCC9, SCC9CAFyn, and SCC9β6 cells expressed keratin with similar rvu(s) (3.9, 3.7 and 3.3, respectively) (Figure 1). The SCC9β6KDFyn cell line did not express any detectable keratin when grown as a monolayer but when grown as a MCS, it expressed low level keratin (rvu: 0.7) (Figure 1), suggesting a neo-expression of keratin in SCC9β6KDFyn MCS. Our results suggest that the three-dimensional cell-cell contact, which occurs during MCS growth, modulates expression of keratin.
MCS formation results in impaired expression of vimentin. Vimentin (VIM) is an intermediate filament routinely found in mesenchymal cells and used to detect cells progressing through EMT (19). When the oral SCC cells were grown as a monolayer, the SCC9CAFyn and SCC9β6KDFyn cell lines expressed VIM with an rvu of 1.0 and 3.5; respectively (Figure 2). Trace amounts of VIM were detected in the SCC9 and SCC9β6 cell lines each with an rvu of 0.2 and 0.1, respectively (Figure 2). This modest expression of VIM was reduced even more when the cells were grown as an MCS, where VIM was detected only in the SCC9β6KDFyn cell line with an rvu of 2.5 (Figure 2).
Fibronectin is differentially expressed by the SCC cells both in monolayers as well as in a MCS. Fibronectin (FN) is a key molecule of ECM and has been identified as a marker for EMT. As a glycoprotein dimer, FN is composed of similar subunits (220 kDa and 240 kDa) linked by 2 disulfide bonds at their C-terminus. To investigate FN's expression, SCC cells were first grown as a monolayer and then evaluated by western blot analysis. A robust expression of FN was detected in SCC9 and SCC9β6 cells (rvu: 2.8 and 2.5; respectively) (Figure 3) while SCC9β6KDFyn and SCC9β6CAFyn cells expressed less FN and had an rvu of 1.0 and 0.8, respectively (Figure 3).
Three-dimensional growth was next evaluated by growing the cells as an MCS. With the exception of the SCC9β6KDFyn cells, overall FN expression of SCC9, SCC9β6 and SCC9CAFyn cells was decreased (rvu: of 1.0, 2.2, and 0.3) (Figure 3). Surprisingly the expression of FN by the SCC9β6KDFyn cell line increased 400% and was assigned an rvu of 4.3 (Figure 3). These results demonstrate a differential expression of FN by the oral SCC cells when grown in a three dimensional environment. These results, plus our previous work demonstrating that other EMT markers (N-cadherin and c-Raf) were upregulated in SCC9β6KDFyn MCS, indicate that the SCC9β6KDFyn cell line is most poised to enter into EMT (7, 20, 21).
Hypoxia and tumor MCS. SCC9β6KDFyn cells are the most potentiated to initiate EMT (7, 14). Due to the close relationship between tumor hypoxia and EMT, we used the SCC9β6KDFyn cells to study hypoxia (7, 20, 21). The SCC9β6KDFyn cells express N-cadherin rather than E-cadherin when grown as an MCS, which is indicative of a motile phenotype (21). To simulate hypoxia, the cultures were incubated in the presence of CoCl2 for 48 h. SCC9β6KDFYN cells grown as MCS under normoxic condition expressed FN (rvu:3.0) (Figure 4). However, when grown in the presence of CoCl2, FN expression was suppressed by 60% (rvu:1.2) (Figure 4). SCC9β6KDFyn cells were also analyzed for N-cadherin expression. N-cadherin expression decreased by 60% when treated with CoCl2. When SCC9β6KDFyn cells were grown as an MCS in a normoxic environment, HIF1α was undetectable. However, when the same cells were incubated in the presence of CoCl2, HIF1α was found to be neo-expressed (rvu: 1.0) (Figure 4). These results indicate the SCC9β6KDFyn cells are able to sustain themselves even in a low oxygen environment and this may confer a growth advantage.
Discussion
The protein content of various oral SCC cells can be indicative of the natural history of the disease. Keratins are the intermediate filament-forming proteins of epithelial cells. The filaments have an important role in epithelial cell protection from mechanical or non-mechanical stresses (22). More recently, keratins have also been recognized as regulators of other cellular properties and functions, including apico-basal polarization, motility, cell size, protein synthesis, and membrane trafficking and signaling. Keratin is altered by malignant transformation and can be used to identify tumors of epithelial origin (23). In this study, we evaluated how oral SCC cells modulate the expression of keratin when grown as a three-dimensional structure composed entirely of tumor cells. When grown in a suspended three-dimensional MCS, all SCC cell lines upregulated keratin expression. SCC9β6KDFYN cells, which did not express keratin when was grown as a monolayer, expressed keratin when grown in MCS (Figure 1).
VIM, a major constituent of the intermediate filament family of proteins, is ubiquitously expressed in normal mesenchymal cells and like keratin, is also a structural protein that helps maintain cell structure and resistance to external stresses. Loss of E-cadherin coupled with N-cadherin expression and acquisition of a fibroblast-like morphology are contributing factors to the process known as epithelial-mesenchymal-transition (EMT). In recent years, VIM has been recognized as a marker for EMT (7, 21). VIM is overexpressed in various epithelial cancers, including prostate, gastrointestinal, central nervous system, breast, melanoma and lung cancer. Overexpression of VIM in cancer correlates well with accelerated tumor growth, invasion and poor prognosis (24). When SCC cells were grown as a monolayer, those containing the Fyn Kinase mutations (kinase-dead or a constitutively active) expressed elevated VIM, indicating an association between Fyn kinase stability and the expression of VIM (Figure 2). When grown as an MCS only the SCC9β6KDFYN cells (kinase-dead FYN) expressed VIM but even this expression was reduced by 33% compared to cells grown in monolayer (Figure 2).
Hypoxia alters cancer cell metabolism and contributes to therapy resistance by inducing cell quiescence. Hypoxia stimulates complex cell signaling networks in cancer, including HIF, PI3K, MAPK, and NFĸB pathways which interact with each other causing positive and negative feedback loops resulting in enhanced or diminished hypoxic effects (25). Over expression of HIF1α may play an adverse role in the malignant progression of head and neck cancer by facilitating the adaptation of cells to the hypoxic state; which then contributes to the invasive properties and angiogenesis in these tumors. Hypoxia is a common characteristic of solid tumors where the centers are typically necrotic (26). Cells that can survive in the absence of oxygen are therefore at a growth advantage compared to cells that cannot. Therefore, MCS, which mimic in vivo tumors with proliferative cells in the periphery and hypoxic centers (27), were used to evaluate hypoxia in vitro. When SCC9β6KDFyn cells were placed under hypoxic conditions a variety of changes occurred such as a 3-fold decrease in FN expression and a 2.5-fold decrease in N-cadherin expression (Figure 4). Tumor growth is complex and our understanding of the process continues to grow. Tumor cells are sensitive to their immediate environment and one might think of that as far targeted therapy. Expression and secretion of specific matrix proteins alters the immediate extracellular matrix. Our results indicate that cellular growth as MCS alters oral SCC cells' protein expression profile and may represent a more realistic cellular model in relation to what is taking place in vivo.
Footnotes
This article is freely accessible online.
- Received October 1, 2016.
- Revision received October 17, 2016.
- Accepted October 24, 2016.
- Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved